Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could ... as the first Advair generic looks to be just around ...
Teva has launched new digital inhaler ... generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol). The competition for the product approved in asthma and COPD ...
Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxtm, today announced ...
DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...
Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...
News Medical on MSN4d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPDA study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
They provided evidence to guide treatment decisions for COPD patients. Study: Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease ...
Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback